Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial
With hallucinations in effectively every high-dose participant, how much of the benefit could be expectancy — and does the phase 3 program address that?
Reasonable evidence with real limitations. how we score evidence
Caveat on this rating: Sponsor-funded with sponsor employees as authors; central raters were blinded, but participants were functionally unblinded by design of the drug itself. Phase 3 toplines (Voyage, Emerge, 2026) are positive but press-release-stage, not yet peer-reviewed.
Two positive phase 3 toplines in 2026 (MDD, GAD) — press-release-stage, not peer reviewed or FDA reviewed. Breakthrough Therapy designation Mar 2024 (GAD).
In 198 adults with moderate-to-severe GAD (phase 2b, five arms), single doses of 100 µg and 200 µg MM120 reduced HAM-A at week 4 by 5.0 and 6.0 points more than placebo respectively (25/50 µg did not separate); perceptual adverse effects were near-universal at active doses (92.5-100%), which tells you blinding was not preserved.
Worth asking
With hallucinations in effectively every high-dose participant, how much of the benefit could be expectancy — and does the phase 3 program address that?
Source
Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial — Robison R, et al. (2025)
Top-tier peer-reviewed journal
Read the source: https://doi.org/10.1001/jama.2025.13481
DOI: 10.1001/jama.2025.13481
How this was scored
- Study design
- Randomised controlled trial
- Funding
- Industry funded
- Published in
- Top-tier peer-reviewed journal
- Sample size
- 198
- Preregistered
- Yes
- Conflicts disclosed
- Yes
- Independent of proponent
- No
- Retracted
- No
Read the full scoring rubric, including what it can't tell you.
Published August 19, 2026.
Questions
How strong is the evidence behind this?
Resolv rates this source "moderate evidence". Reasonable evidence with real limitations. It scores 59 out of 100 on our published rubric. One caveat travels with that badge: Sponsor-funded with sponsor employees as authors; central raters were blinded, but participants were functionally unblinded by design of the drug itself. Phase 3 toplines (Voyage, Emerge, 2026) are positive but press-release-stage, not yet peer-reviewed. The score is calculated from recorded facts about the source — study design, funding, publication venue, sample size, preregistration — not typed in by an editor.
What is the source for this?
Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial — Robison R, et al. (2025). Published in: Top-tier peer-reviewed journal. DOI: 10.1001/jama.2025.13481. The full source is linked on this page so you can read it yourself.
Who paid for this research, and does that matter?
Study design: Randomised controlled trial. Funding: Industry funded. The researchers were not independent of whoever benefits from the result. Industry sponsorship is one of the most reliably measured biases in medicine, which is why funding carries real weight in the score rather than sitting in a footnote.
Is lsd, lysergide, mm120 FDA approved for this use?
No. Its current status is: Phase 3 trials. Two positive phase 3 toplines in 2026 (MDD, GAD) — press-release-stage, not peer reviewed or FDA reviewed. Breakthrough Therapy designation Mar 2024 (GAD).
Is this medical advice?
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.